- Home
- NBTB vs SLNO Comparison
NBTB vs SLNO Comparison
Compare NBTB & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTB
- SLNO
- Stock Information
- Founded
- NBTB 1856
- SLNO 1999
- Country
- NBTB United States
- SLNO United States
- Employees
- NBTB N/A
- SLNO N/A
- Industry
- NBTB Major Banks
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NBTB Finance
- SLNO Health Care
- Exchange
- NBTB Nasdaq
- SLNO Nasdaq
- Market Cap
- NBTB 2.3B
- SLNO 3.8B
- IPO Year
- NBTB N/A
- SLNO 2014
- Fundamental
- Price
- NBTB $44.19
- SLNO $56.58
- Analyst Decision
- NBTB Buy
- SLNO Strong Buy
- Analyst Count
- NBTB 3
- SLNO 10
- Target Price
- NBTB $52.33
- SLNO $112.50
- AVG Volume (30 Days)
- NBTB 152.4K
- SLNO 1.8M
- Earning Date
- NBTB 10-27-2025
- SLNO 11-05-2025
- Dividend Yield
- NBTB 3.38%
- SLNO N/A
- EPS Growth
- NBTB 7.37
- SLNO N/A
- EPS
- NBTB 2.77
- SLNO N/A
- Revenue
- NBTB $591,283,000.00
- SLNO $32,656,999.00
- Revenue This Year
- NBTB $27.02
- SLNO N/A
- Revenue Next Year
- NBTB $11.44
- SLNO $181.85
- P/E Ratio
- NBTB $15.80
- SLNO N/A
- Revenue Growth
- NBTB 14.42
- SLNO N/A
- 52 Week Low
- NBTB $37.31
- SLNO $41.50
- 52 Week High
- NBTB $52.44
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- NBTB 56.56
- SLNO 36.98
- Support Level
- NBTB $41.89
- SLNO $48.91
- Resistance Level
- NBTB $43.79
- SLNO $72.99
- Average True Range (ATR)
- NBTB 0.91
- SLNO 4.52
- MACD
- NBTB -0.13
- SLNO -1.00
- Stochastic Oscillator
- NBTB 67.85
- SLNO 31.87
About NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.